title: Influence of minor groove binders on the eukaryotic topoisomerase II cleavage reaction with 41 base pair model oligonucleotides.
abstract: This report deals with the cleavage reaction of calf thymus (CT) topoisomerase II with oligonucleotides containing one main cleavage site and adjacent binding sites for minor groove binders. The sequences of the oligonucleotides were derived from a pBR 322 sequence, which contains one main topoisomerase II cleavage site. The cleavage reaction was performed under increasing concentrations of minor groove binders and it showed characteristic inhibition dependences of topoisomerase II to the binding sites and to the binding length of the minor groove binders. The extension of the minor groove binder length on DNA from 4 to 10 base pairs (bp) by netropsin and bis-netropsin, respectively, causes a strong increase of the topoisomerase II cleavage inhibition. The same is observed by the introduction of a second minor groove binder sequence symmetrically positioned around the topoisomerase II main cleavage site. The combination of two different minor groove binders can lead to an increased topoisomerase II inhibition but also to a prevention of total inhibition as shown with chromomycin A3 and distamycin A at concentrations of 0.1 and 0.25 microM, respectively.
authors.affiliation: Institut für Molekulare Biotechnologie e.V., Jena, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Bell
authors.forename: L
authors.initials: L
authors.lastname: Kittler
authors.forename: G
authors.initials: G
authors.lastname: Löber
authors.forename: C
authors.initials: C
authors.lastname: Zimmer
mesh_terms: D000818:Animals; D001345:Autoradiography; D001483:Base Sequence; D001665:Binding Sites; D002417:Cattle; D014128:Chromomycin A3 / Q000378:metabolism / Q000494:pharmacology*; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004214:Distamycins / Q000378:metabolism / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D009429:Netropsin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D009841:Oligonucleotides / Q000378:metabolism*; D059005:Topoisomerase II Inhibitors
chemical_list: D004214:Distamycins; D004791:Enzyme Inhibitors; D007211:Indoles; D009841:Oligonucleotides; D059005:Topoisomerase II Inhibitors; C007293:DAPI; D009429:Netropsin; C032161:bis-netropsin; C030000:stallimycin; D004247:DNA; D014128:Chromomycin A3; D004250:DNA Topoisomerases, Type II